Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire joins Proactive's Stephen Gunnion with details of two significant research grants in Belgium.
The grants, aimed at fostering collaborations in advanced therapy medicinal products (ATMPs), notably support partnerships with EXO Biologics for exosome manufacturing and Revatis SA focusing on sarcopenia research.
Sarcopenia, an age-related muscle loss condition, is a key area of Genflow's research. Dr Leire emphasized the importance of maintaining muscle mass for longevity and overall health. The Belgian government's non-dilutive funding covers 80% of the project costs, providing substantial financial support for Genflow. This funding setup is particularly beneficial as it offers more cash flow, shareholder value protection, and serves as a stamp of approval for the scientific rigour of Genflow's research.
These collaborations are part of a three-year plan to build a robust biotech ecosystem in Belgium, involving academic centers and various biotech actors. This initiative is expected to significantly enhance Genflow’s research capabilities and increase its company valuation through the achievement of meaningful milestones.
Beyond these partnerships, Genflow is actively seeking further collaborations to expand its pipeline, focusing on gene therapy and age-related diseases. This strategy aims to reduce both financial and scientific risks in the current challenging biotech market, ensuring a diversified and robust research portfolio for the company.
